Overview |
bsm-52259r-100ul |
ERK1/2 Recombinant Antibody |
WB, FCM, IHC-P, IF(ICC) |
Human, Mouse, Rat, Zebrafish |
Specifications |
Unconjugated |
Rabbit |
Recombinant Human ERK1 + ERK2 between 150 amino acids to C-terminus |
Recombinant |
IgG |
Lot dependent |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Store at -20°C for 12 months. |
Target |
P27361, P28482 |
ERK 1; ERK 2; ERK-2; ERK1; erk1/2; ERK2; ERT1; ERT2; Extracellular signalregulated kinase 1; Extracellular signal-regulated kinase 2; MAP kinase 1; MAP kinase 2; MAP kinase isoform p42; MAP kinase isoform p44; MAPK 1; MAPK 2; MAPK 3; Mapk1; MAPK2; MAPK3;Mitogen-activated protein kinase 1; Mitogenactivated protein kinase 2; MK01_HUMAN; p38; p40; p41; p42-MAPK; PRKM 2 |
p44/42 MAP Kinase(Thr202); ERK (extracellular signal regulated kinase), also known as MAPK (mitogen activated protein kinase) has two closely related isoforms of 44 kDa and 42 kDa, respectively. These kinases belong to a family of serine/threonine kinases that are activated upon treatment of cells with a large variety of stimuli including mitogens, hormones, growth factors, cytokines, and bioactive peptides. Cell stimulation induces the activation of a signaling cascade, the downstream effects of which have been linked to the regulation of cell growth and differentiation as well as the cytoskeleton. ERK1 and ERK2 are phosphorylated within the activation loop on both a Threonine and a Tyrosine residue (within a Thr-Glu-Tyr motif) by MEKs (MAPK/ERK kinases), thereby greatly elevating the activity of ERK1&2. |
Application Dilution |
WB |
1:300-5000 |
FCM |
1:20-100 |
IHC-P |
1:200-400 |
IF(ICC) |
1:50-200 |